BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05180240 (CardiolRx in Acute Myocarditis): BVCT ex-ante prediction vs. reported outcome

On 19 Oct 2024, BioinvestGPT's BVCT predicted technical partial success and commercial partial success for this trial. The 6 Aug 2025 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically maybe significant and commercially maybe sufficient.

Clinical Trial

NCTID
NCT05180240
Acronym
ARCHER
Drug Name
CardiolRx
Drug MoA
oral cannabidiol
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Cardiovascular Diseases
Indication
Acute Myocarditis
Human Patients
109
Sponsor
Cardiol Therapeutics
Phase
Phase 2

Prediction of , index 1805

Prospective Prediction
Prediction Index
1805
Prediction Date
Commercial Prediction
partial SUCCESS (commercially maybe sufficient clinical benefit in LVEF/KCCQ/mortality non-superior to beta blockers yet there is no FDA approved treatments specifically for acute myocarditis)
Technical Prediction
partial SUCCESS (statistically maybe significant yet moderate clinical benefit in LVEF/KCCQ/mortality against placebo)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
291 days in advance
Readout Data Interpretation
CardiolRx has met the ECV primary endpoint (p=0.0538) and has not met its GLS primary endpoint
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically maybe significant and commercially maybe sufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
Impact of CardiolRx on Myocardial Recovery in Acute Myocarditis. A Double-blind, Placebo-controlled Trial
Phase
Phase 2
Status
Completed
Enrollment
109
Lead sponsor
Cardiol Therapeutics Inc.
Conditions
Acute Myocarditis
Interventions
DRUG: CardiolRx
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2022-07-28
Primary completion
2025-01-31
Completion
2025-02-04
Results first posted
2026-06-17
Primary outcomes
  • Extracellular Volume (ECV) (12 weeks post randomization)
  • Global Longitudinal Strain (GLS) (12 weeks post randomization)

NCT05180240 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials